This Cathie Wood Stock Is Poised to Double, Says Wall Street
Gene-editing specialist Intellia Therapeutics (NASDAQ: NTLA) has caught the attention of Cathie Wood. The founder and CEO of Ark Invest, an investment management firm focused on investing in innovative companies, includes Intellia as a top 10 holding in one of her firm's actively managed ETFs.
Other actors on Wall Street seem to agree with the pick. The biotech's current price target of $84.22 (according to Yahoo! Finance) represents an upside of about 190% over its current share price of just under $29. Can Intellia Therapeutics live up to this optimism? Let's find out.
Intellia's market capitalization is $2.56 billion. That's despite the fact that the company has no product on the market. And even worse, none of its programs are yet in late-stage clinical trials. It's always hard to value clinical-stage biotech stocks, but at first glance, this market cap seems too high. The market must be valuing the company's candidates highly.
Source Fool.com
Intellia Therapeutics Inc Aktie
Durchaus positiv bewertet unsere Community derzeit Intellia Therapeutics Inc mit 15 Buy-Einschätzungen und 1 Sell-Einschätzungen.
Für Intellia Therapeutics Inc wird ein Kursziel von 60 € erwartet, was eine deutliche Steigerung gegenüber dem aktuellen Kurs von 17.79 € darstellt.
